A voluntary program designed to help Medicare Part D beneficiaries manage drug costs could provide considerable benefit to people with cancer, according to study results.The Medicare Prescription Paym ...

The Inflation Reduction Act (IRA) promised big changes for Medicare Part D beneficiaries. Beginning in 2026, patients’ annual out-of-pocket (OOP) costs for Part D drugs are capped at $2,100, and the ...

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study Early-year entry into catastrophic ...

NEW YORK, March 27, 2024 /PRNewswire/ -- Capital Rx, the full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA) advancing our nation's healthcare infrastructure to ...